NClip

Antiviral Medications

6 min read

Antiviral Medications

Key Points

  • Antiviral drugs are used for selected viral infections.
  • Major subclasses include antiherpes, antiinfluenza, antihepatitis, and antiretrovirals.
  • Core action pattern is inhibition of viral reproduction at different life-cycle stages.
  • Antivirals are class-specific and virus-specific; selection depends on infection type and treatment timing.
  • COVID-19 antivirals are time-sensitive and require medication-interaction screening before initiation.
  • Antibiotics do not treat viral infections.

Class Overview

Antiviral therapy targets viral life-cycle steps to reduce viral burden and disease progression. Because viral structure and replication vary by pathogen, antiviral treatment is not one-size-fits-all and should match the suspected or confirmed virus.

Unlike bacteria, viruses depend on host-cell machinery for replication. This is why many viral infections are self-limited and why antiviral timing and host-risk stratification strongly affect benefit.

Subclass Highlights

Antiherpes Agents (Acyclovir)

  • Mechanism: Acyclovir causes viral DNA chain termination during viral replication.
  • Common indications: Herpes and varicella-family infections (for example genital herpes, chickenpox, shingles), plus selected Epstein-Barr and cytomegalovirus treatment pathways.
  • Administration: PO, IV, or topical routes are used; avoid IM/subcutaneous use. Give IV infusions over at least 1 hour to reduce renal tubular injury risk.
  • Teaching priorities: Start early after symptom onset, encourage fluid intake, and avoid sexual contact while genital lesions are present.
  • Episodic vs suppressive use: Episodic therapy is most effective when started within about 24 hours of lesion onset; chronic suppressive use lowers outbreak frequency and transmission risk.
  • Expected effect limits: Not curative for herpes, but can reduce lesion severity/duration and may be used in lower-dose suppression regimens.
  • Safety focus: Monitor for nephrotoxicity, GI upset, renal impairment, and lowered seizure threshold.

Antiinfluenza Agents (Oseltamivir)

  • Mechanism: Oseltamivir blocks release of influenza virus from infected cells.
  • Timing-critical indication: Best symptom reduction occurs when started within 48 hours of influenza symptom onset.
  • Other uses: Postexposure or prophylactic pathways in high-risk settings.
  • Administration: Oral dosing; give with food to reduce GI upset.
  • Alternative route option: Inhaled zanamivir may be used when oral therapy is unsuitable but should be avoided in asthma/COPD because bronchospasm risk is clinically significant.
  • Hospital/route alternative: IV peramivir can be used in selected moderate-to-severe influenza pathways when oral/inhaled options are not practical.
  • Vaccine counseling: Oseltamivir does not replace annual influenza vaccination.
  • Safety focus: Monitor for GI upset, serious skin hypersensitivity reactions, and neuropsychiatric symptoms (especially in children).
  • Use caution: Renal failure, chronic cardiac or respiratory disease, or any condition that may require imminent hospitalization.

Antihepatitis Agents (Adefovir)

  • Mechanism: Nucleoside/nucleotide analogs inhibit viral DNA polymerase and can terminate viral DNA-chain elongation.
  • Common indications: Chronic HBV suppression pathways and HCV direct-acting antiviral (DAA) cure regimens.
  • Treatment pattern: Prolonged therapy (often >1 year or indefinite) to maintain or improve liver function when active disease is present.
  • Safety focus: Severe acute HBV exacerbation risk, nephrotoxicity, lactic acidosis, and severe hepatomegaly.
  • Teaching priorities: Offer HIV testing before/during treatment, teach not to stop medication without provider direction, and monitor hepatic function for several months after therapy is stopped.
  • Resistance caution: Unrecognized HIV in chronic HBV contexts can increase antiretroviral resistance risk.
  • HCV adherence priority: DAA regimens (for example sofosbuvir-based) can achieve virologic cure when taken for the full 12-24 week course; incomplete suppression increases resistance risk.
  • Mechanism: Impede HIV replication and are used in ART regimens.
  • Prototype example: Lamivudine-zidovudine combinations for HIV care.
  • Dosing caution: Lamivudine formulations for HIV-1 use higher active-dose content than HBV-only forms; use HIV-appropriate products in HIV treatment.
  • Teaching priorities: Reinforce that ART does not cure HIV and transmission can still occur; pair treatment with safer-sex and blood-exposure prevention practices.
  • Safety focus: Monitor urine output and renal labs; watch for lactic acidosis and severe hepatomegaly.
  • Urgent escalation: Stop medication and notify the provider if pancreatitis symptoms occur (for example sudden abdominal pain, nausea, or jaundice).

Anti-COVID-19 Antiviral Pathways

  • Nirmatrelvir/ritonavir (Paxlovid): Nirmatrelvir inhibits viral protease; ritonavir boosts levels through strong CYP3A4 inhibition. Review full medication profile before initiation due to high interaction risk.
  • Timing window: Start nirmatrelvir/ritonavir as soon as possible and no later than about 5 days from symptom onset.
  • Remdesivir: IV RNA-polymerase inhibitor generally used when oral therapy is not suitable or when symptom onset window extends beyond oral-option criteria (commonly within about 7 days). Monitor renal function and infusion hypersensitivity risk.
  • Molnupiravir: Oral RNA-error induction strategy used when preferred options are unsuitable (for example interaction burden or renal constraints); initiate within about 5 days of symptom onset.
  • Oxygen-requiring inpatient context: Dexamethasone is a common non-antiviral adjunct to reduce inflammatory lung injury in severe hospitalized COVID-19 illness.

Nursing Considerations

  • Verify the infection pattern supports antiviral rather than antibacterial treatment.
  • Reinforce adherence to prescribed antiviral regimen and follow-up plans.
  • Teach that many antivirals can reduce severity or duration but may not cure the underlying viral infection.
  • Encourage hydration and monitor renal function closely for renally cleared antivirals (for example acyclovir/valacyclovir pathways).
  • Monitor CBC when marrow suppression risk is present and assess mental-status changes in clients receiving IV antivirals with renal impairment.
  • For ritonavir-containing regimens, perform interaction-focused medication reconciliation before first dose and during treatment changes.
  • For anti-COVID treatment, confirm symptom-onset timing before initiation to avoid late, low-benefit starts.
  • Monitor for progression despite treatment and escalate when respiratory or hemodynamic instability appears.
  • Reinforce fatigue management with planned rest periods during therapy when symptoms are significant.

High-Risk Safety Alerts

  • Ganciclovir: Severe marrow suppression risk (granulocytopenia, anemia, thrombocytopenia, pancytopenia) and reproductive toxicity/carcinogenicity concerns.
  • Cidofovir: Major nephrotoxicity risk; avoid with other nephrotoxic agents.
  • Sofosbuvir pathways: Monitor for HBV reactivation risk in HBV/HCV coinfection.
  • Tenofovir pathways: Stopping therapy can precipitate acute HBV exacerbation; do not discontinue without supervised follow-up.

Self-Check

  1. Why is pathogen-specific diagnosis important before selecting antiviral therapy?
  2. Why is oseltamivir effectiveness strongly linked to the first 48 hours of symptoms?
  3. Which organ systems require close monitoring when using antihepatitis antivirals?

Graph View